Giulio Maria Pasinetti

List of Publications by Year
in descending order

284 papers	15,732 citations	12303 69 h-index	20307 116 g-index
322 all docs	322 docs citations	322 times ranked	17179 citing authors

#	Article	IF	Citations
1	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.4	5
2	Changes in polyphenol serum levels and cognitive performance after dietary supplementation with Concord grape juice in veterans with Gulf War Illness. Life Sciences, 2022, 292, 119797.	2.0	3
3	A common language for Gulf War Illness (GWI) research studies: GWI common data elements. Life Sciences, 2022, 290, 119818.	2.0	9
4	Recent Advances in Research on Polyphenols: Effects on Microbiota, Metabolism, and Health. Molecular Nutrition and Food Research, 2022, 66, e2100670.	1.5	48
5	Role of Polyphenol-Derived Phenolic Acid in Mitigation of Inflammasome-Mediated Anxiety and Depression. Biomedicines, 2022, 10, 1264.	1.4	5
6	Flavonoids Ameliorate Stress-Induced Depression by Preventing NLRP3 Inflammasome Priming. Current Developments in Nutrition, 2022, 6, 802.	0.1	0
7	Chronic Stress-Induced Depression and Anxiety Priming Modulated by Gut-Brain-Axis Immunity. Current Developments in Nutrition, 2022, 6, 801.	0.1	0
8	Microbiota Metabolites Modulate the T Helper 17 to Regulatory T Cell (Th17/Treg) Imbalance Promoting Resilience to Stress-Induced Anxiety- and Depressive-Like Behaviors. Current Developments in Nutrition, 2022, 6, 803.	0.1	0
9	Synbiotic-Derived Metabolites Reduce Neuroinflammatory Symptoms of Alzheimerâ€™s Disease. Current Developments in Nutrition, 2022, 6, 804.	0.1	0
10	Investigation of Potential Brain Microbiome in Alzheimerâ€™s Disease: Implications of Study Bias. Advances in Alzheimer's Disease, 2022, , .	0.2	0
11	The Role of the Gut Microbiota in the Metabolism of Polyphenols as Characterized by Gnotobiotic Mice. Advances in Alzheimer's Disease, 2022, , .	0.2	0
12	Microbiota metabolites modulate the T helper 17 to regulatory T cell (Th17/Treg) imbalance promoting resilience to stress-induced anxiety- and depressive-like behaviors. Brain, Behavior, and Immunity, 2021, 91, 350-368.	2.0	64
13	Neuronal Pentraxin 1 Promotes Hypoxic-Ischemic Neuronal Injury by Impairing Mitochondrial Biogenesis via Interactions With Active Bax[6A7] and Mitochondrial Hexokinase II. ASN Neuro, 2021, 13, 175909142110128.	1.5	4
14	UGT84F9 is the major flavonoid UDP-glucuronosyltransferase inMedicago truncatula. Plant Physiology, 2021, 185, 1617-1637.	2.3	11
15	Anxiolytic effects of NLRP3 inflammasome inhibition in a model of chronic sleep deprivation. Translational Psychiatry, 2021, 11, 52.	2.4	19
16	Editorial: Psychiatric Disorder in Veterans. Frontiers in Psychiatry, 2021, 12, 666719.	1.3	2
17	The Inhibition of Caspase-1 Activity With a Dietary Polyphenol Reduces Anxiety and Depression in a Murine Model of Chronic Stress. Current Developments in Nutrition, 2021, 5, 368.	0.1	0
18	Microbiota Metabolites Modulate the T Helper 17 to Regulatory T Cell (Th17/Treg) Imbalance Promoting Resilience to Stress-Induced Anxiety- and Depressive-Like Behaviors. Current Developments in Nutrition, 2021, 5, 917.	0.1	0

#	Article	IF	Citations
19	Sensitization to Chronic Stress-Induced Depression and Anxiety Modulated by Gut-Brain-Axis Immunity. Current Developments in Nutrition, 2021, 5, 1174.	0.1	0
20	Chronic Stress-Induced Depression and Anxiety Priming Modulated by Gut-Brain-Axis Immunity. Frontiers in Immunology, 2021, 12, 670500.	2.2	54
21	Discovery and characterization of small-molecule inhibitors of NLRP3 and NLRC4 inflammasomes. Journal of Biological Chemistry, 2021, 296, 100597.	1.6	13
22	Optimization of probiotic therapeutics using machine learning in an artificial human gastrointestinal tract. Scientific Reports, 2021, 11, 1067.	1.6	17
23	Dissolution Study on Grape Polyphenol Hard Gelatin Capsule Dietary Supplements. Frontiers in Nutrition, 2021, 8, 780260.	1.6	4
24	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles. Frontiers in Nutrition, 2021, 8, 780226.	1.6	1
25	COVID-19 and Alzheimer's disease: Meninges-mediated neuropathology.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056418.	0.4	1
26	Grape-Derived Polyphenols Ameliorate Stress-Induced Depression by Regulating Synaptic Plasticity. Journal of Agricultural and Food Chemistry, 2020, 68, 1808-1815.	2.4	17
27	The Use of Antimicrobial and Antiviral Drugs in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 4920.	1.8	28
28	Efficient Chemical Synthesis of (Epi)catechin Glucuronides: Brain-Targeted Metabolites for Treatment of Alzheimerâ€™s Disease and Other Neurological Disorders. ACS Omega, 2020, 5, 30095-30110.	1.6	5
29	The Viral Hypothesis in Alzheimerâ€™s Disease: Novel Insights and Pathogen-Based Biomarkers. Journal of Personalized Medicine, 2020, 10, 74.	1.1	12
30	Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes. Molecular Immunology, 2020, 125, 172-177.	1.0	6
31	The Innate Immune System and Inflammatory Priming: Potential Mechanistic Factors in Mood Disorders and Gulf War Illness. Frontiers in Psychiatry, 2020, 11, 704.	1.3	15
32	Effect of polyphenol treatment for mild cognitive impairment (MCI) and diabetes. Alzheimer's and Dementia, 2020, 16, e044062.	0.4	1
33	A novel gut microbiome therapeutic derived from dietary polyphenols attenuates neuroinflammation in vivo in a model of c9orf72 mediated frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e046032.	0.4	0
34	Brain bioavailable microbiome derived flavonoid metabolite attenuates neuroinflammation in C9orf72 associated frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e046035.	0.4	0
35	Defining the role of gut microbiotaâ€derived ketamine metabolites in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e046152.	0.4	1
36	Diesel exhaust particle role on gut microbiome and onset of Alzheimer disease neuroinflammation. Alzheimer's and Dementia, 2020, 16, e046266.	0.4	0

#	Article	IF	Citations
37	Glucuronidation of Methylated Quercetin Derivatives: Chemical and Biochemical Approaches. Journal of Agricultural and Food Chemistry, 2020, 68, 14790-14807.	2.4	9
38	Peroxisome Proliferator Activator Receptor Gamma Coactivator-1Î± Overexpression in Amyotrophic Lateral Sclerosis: A Tale of Two Transgenics. Biomolecules, 2020, 10, 760.	1.8	3
39	Gut Microbiome-Modified Polyphenolic Compounds Inhibit Î±-Synuclein Seeding and Spreading in Î±-Synucleinopathies. Frontiers in Neuroscience, 2020, 14, 398.	1.4	17
40	The role of the exposome in promoting resilience or susceptibility after SARS-CoV-2 infection. Journal of Exposure Science and Environmental Epidemiology, 2020, 30, 776-777.	1.8	10
41	The dichotomous role of the gut microbiome in exacerbating and ameliorating neurodegenerative disorders. Expert Review of Neurotherapeutics, 2020, 20, 673-686.	1.4	26
42	Potential Novel Role of COVID-19 in Alzheimerâ€™s Disease and Preventative Mitigation Strategies. Journal of Alzheimer's Disease, 2020, 76, 21-25.	1.2	97
43	Prophylactic effect of flavanol rich preparation metabolites in promoting resilience to a mouse model of social stress. Translational Psychiatry, 2020, 10, 183.	2.4	8
44	Anti-aggregation Effects of Phenolic Compounds on Î±-synuclein. Molecules, 2020, 25, 2444.	1.7	18
45	Synbiotic-Derived Metabolites Reduce Neuroinflammatory Symptoms of Alzheimerâ€™s Disease. Current Developments in Nutrition, 2020, 4, nzaa062_035.	0.1	2
46	The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process. Cells, 2020, 9, 1552.	1.8	33
47	Flavonoids Ameliorate Stress-Induced Depression by Preventing NLRP3 Inflammasome Priming. Current Developments in Nutrition, 2020, 4, nzaa057_047.	0.1	1
48	Pine Bark Polyphenolic Extract Attenuates Amyloid-Î² and Tau Misfolding in a Model System of Alzheimerâ€™s Disease Neuropathology1. Journal of Alzheimer's Disease, 2020, 73, 1597-1606.	1.2	9
49	Investigation of Potential Brain Microbiome in Alzheimerâ€™s Disease: Implications of Study Bias. Journal of Alzheimer's Disease, 2020, 75, 559-570.	1.2	17
50	Safety, Tolerability and Efficacy of Dietary Supplementation with Concord Grape Juice in Gulf War Veterans with Gulf War Illness: A Phase I/IIA, Randomized, Double-Blind, Placebo-Controlled Trial. International Journal of Environmental Research and Public Health, 2020, 17, 3546.	1.2	10
51	Design of a Novel Synbiotic Formulation to Optimize Gut-derived Phenolic Acid Mediated Gut-brain Axis Signals for the Treatment of Stress-induced Depression and Anxiety (OR23-03-19). Current Developments in Nutrition, 2019, 3, nzz040.OR23-03-19.	0.1	2
52	Polyphenolic Compounds Ameliorate Stress-induced Depression by Preventing NLRP3 Inflammasome Priming (P19-011-19). Current Developments in Nutrition, 2019, 3, nzz049.P19-011-19.	0.1	4
53	The Gut Microbiota Links Dietary Polyphenols With Management of Psychiatric Mood Disorders. Frontiers in Neuroscience, 2019, 13, 1196.	1.4	61
54	Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2019, 168, 147-181.	0.9	21

#	Article	IF	Citations
55	Dietary polyphenols as a safe and novel intervention for modulating pain associated with intervertebral disc degeneration in an in-vivo rat model. PLoS ONE, 2019, 14, e0223435.	1.1	13
56	The Gut Microbiota Composition Affects Polyphenol-mediated Cognitive Resilience in Mice by Modulating the Bioavailability of Phenolic Acids (P20-038-19). Current Developments in Nutrition, 2019, 3, nzz040.P20-038-19.	0.1	1
57	An Efficient Synthesis of Deoxyrhapontigenin-3-O-Î²-<scp>d</scp>-glucuronide, a Brain-Targeted Derivative of Dietary Resveratrol, and Its Precursor 4â€²-O-Me-Resveratrol. ACS Omega, 2019, 4, 8222-8230.	1.6	4
58	Grapeâ€derived polyphenols produce antidepressant effects via VGFâ€•and BDNFâ€dependent mechanisms. Annals of the New York Academy of Sciences, 2019, 1455, 196-205.	1.8	13
59	The gut microbiota composition affects dietary polyphenols-mediated cognitive resilience in mice by modulating the bioavailability of phenolic acids. Scientific Reports, 2019, 9, 3546.	1.6	61
60	PRIMING OF MICROGLIA ACTIVITY INCREASES SUSCEPTIBILITY TO DEPRESSION-LIKE BEHAVIORS. Innovation in Aging, 2019, 3, S95-S95.	0.0	0
61	TARGETING THE NLRP3 INFLAMMASOME IN MECHANISMS OF SLEEP DEPRIVATION-INDUCED NEUROINFLAMMATION. Innovation in Aging, 2019, 3, S95-S96.	0.0	1
62	Mechanisms of Immune Activation by c9orf72-Expansions in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2019, 13, 1298.	1.4	28
63	Heterogeneity in gut microbiota drive polyphenol metabolism that influences Î±-synuclein misfolding and toxicity. Journal of Nutritional Biochemistry, 2019, 64, 170-181.	1.9	52
64	Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets. British Journal of Pharmacology, 2019, 176, 3558-3584.	2.7	17
65	Polyphenolic Compounds Alter Stressâ€Induced Patterns of Global DNA Methylation in Brain and Blood. Molecular Nutrition and Food Research, 2018, 62, e1700722.	1.5	19
66	The Role of the Gut Microbiota in the Metabolism of Polyphenols as Characterized by Gnotobiotic Mice. Journal of Alzheimer's Disease, 2018, 63, 409-421.	1.2	63
67	Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice. Nature Communications, 2018, 9, 477.	5.8	185
68	Endoscopic retrograde cholangiopancreatography in the elderly: results of a retrospective study and a geriatriciansâ€™ point of view. BMC Gastroenterology, 2018, 18, 38.	0.8	28
69	A Comprehensive Database and Analysis Framework To Incorporate Multiscale Data Types and Enable Integrated Analysis of Bioactive Polyphenols. Molecular Pharmaceutics, 2018, 15, 840-850.	2.3	4
70	Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimerâ€™s disease-type beta-amyloid neuropathological mechanisms. Expert Review of Neurotherapeutics, 2018, 18, 83-90.	1.4	247
71	Development and validation of an ultra-high performance liquid chromatography/triple quadrupole mass spectrometry method for analyzing microbial-derived grape polyphenol metabolites. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1099, 34-45.	1.2	17
72	An Extract of Artemisia dracunculus L. Promotes Psychological Resilience in a Mouse Model of Depression. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-9.	1.9	13

#	Article	IF	Citations
73	Targeted analysis of microbial-generated phenolic acid metabolites derived from grape flavanols by gas chromatography-triple quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 374-383.	1.4	14
74	Dietary polyphenols promote resilience against sleep deprivationâ€induced cognitive impairment by activating protein translation. FASEB Journal, 2018, 32, 5390-5404.	0.2	18
75	Epigenetic modifications by polyphenolic compounds alter gene expression in the hippocampus. Biology Open, 2018, 7, .	0.6	14
76	Dietary polyphenols enhance optogenetic recall of fear memory in hippocampal dentate gyrus granule neuron subpopulations. Communications Biology, 2018, 1, 42.	2.0	6
77	Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols. Frontiers in Pharmacology, 2018, 9, 867.	1.6	29
78	Principles of inflammasome priming and inhibition: Implications for psychiatric disorders. Brain, Behavior, and Immunity, 2018, 73, 66-84.	2.0	88
79	Autonomic Nervous System Dysfunctions as a Basis for a Predictive Model of Risk ofÂNeurological Disorders in Subjects withÂPrior History of Traumatic Brain Injury: Implications in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 305-315.	1.2	4
80	Association Between Preoperative Malnutrition and Postoperative Delirium After Hip Fracture Surgery in Older Adults. Journal of the American Geriatrics Society, 2017, 65, 1222-1228.	1.3	88
81	Influence of diabetes on plasma pharmacokinetics and brain bioavailability of grape polyphenols and their phase II metabolites in the Zucker diabetic fatty rat. Molecular Nutrition and Food Research, 2017, 61, 1700111.	1.5	37
82	Glucuronidated Flavonoids in Neurological Protection: Structural Analysis and Approaches for Chemical and Biological Synthesis. Journal of Agricultural and Food Chemistry, 2017, 65, 7607-7623.	2.4	28
83	Role of the Microbiome in Polyphenol Metabolite-Mediated Attenuation of Î²-amyloid and tau Protein Misfolding in Alzheimerâ€™s Disease. , 2017, , 281-304.		0
84	The effect of obesity and repeated exposure on pharmacokinetic response to grape polyphenols in humans. Molecular Nutrition and Food Research, 2017, 61, 1700043.	1.5	32
85	P2â€047: Novel Role of The Neurospecific SCF^{FBX2}â€Ł3â€Ligase in Mechanisms Associated with The Promotion of Synaptic Plasticity Through Rescue of CAMPâ€CREB Signaling Pathway in a Model of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P625.	0.4	0
86	O1â€04â€01: Repurposing a Drug for Treatment of Prostate Cancer for Prevention of Dementia in Parkinsonâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P179.	0.4	0
87	Hip Fracture Surgery and Survival in Centenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 1514-1518.	1.7	11
88	Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain. Journal of Alzheimer's Disease, 2016, 54, 477-496.	1.2	10
89	P1â€093: Characterization of Novel Bioavailable Bioactive Polyphenolic Compounds for Pharmacological Preservation of Blood Brain Barrier Function in Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P436.	0.4	0
90	O2-02-04: Protective Roles of Intestinal Microbiota in Alzheimerâ€™s Disease Through Mechanisms Involving Short Chain Fatty Acids and Phenolic Acids. , 2016, 12, P224-P225.		1

#	Article	IF	Citations
91	In Silico Modeling of Novel Drug Ligands for Treatment of Concussion Associated Tauopathy. Journal of Cellular Biochemistry, 2016, 117, 2241-2248.	1.2	1
92	Recommendations for Development of Botanical Polyphenols as â€œNatural Drugsâ€•for Promotion of Resilience Against Stress-Induced Depression and Cognitive Impairment. NeuroMolecular Medicine, 2016, 18, 487-495.	1.8	23
93	Biomarkers of Resilience in Stress Reduction for Caregivers of Alzheimerâ€™s Patients. NeuroMolecular Medicine, 2016, 18, 177-189.	1.8	18
94	Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease. Oncotarget, 2016, 7, 7469-7479.	0.8	30
95	Recommendations for Development of New Standardized Forms of Cocoa Breeds and Cocoa Extract Processing for the Prevention of Alzheimerâ€™s Disease: Role of Cocoa in Promotion of Cognitive Resilience and Healthy Brain Aging. Journal of Alzheimer's Disease, 2015, 48, 879-889.	1.2	18
96	ISDN2014_0294: REMOVED: Insulin resistance and obesity in childhood and long term consequences during aging. International Journal of Developmental Neuroscience, 2015, 47, 88-88.	0.7	0
97	O1-11-05: Targeting multiple disease mechanisms for the treatment of Alzheimer's disease with biosynthetic polyphenol metabolites and their precursor pro-drugs in vivo. , 2015, 11, P158-P158.		1
98	Inhibiting amyloid Î²â€protein assembly: Sizeâ€“activity relationships among grape seedâ€derived polyphenols. Journal of Neurochemistry, 2015, 135, 416-430.	2.1	28
99	Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. Neuropsychiatric Disease and Treatment, 2015, 11, 565.	1.0	13
100	P2-315: Preservation of synaptic plasticity and neuronal integrity in a mouse model of Alzheimer's disease. , 2015, 11, P614-P614.		0
101	P4-155: Intestinal microbiota-derived phenol acids are capable of accumulating in the brain and interfere with Î²-amyloid oligomerization. , 2015, 11, P838-P838.		0
102	Synthesis and Quantitative Analysis of Plasma-Targeted Metabolites of Catechin and Epicatechin. Journal of Agricultural and Food Chemistry, 2015, 63, 2233-2240.	2.4	22
103	Role of intestinal microbiota in the generation of polyphenolâ€derived phenolic acid mediated attenuation of Alzheimer's disease Î²â€amyloid oligomerization. Molecular Nutrition and Food Research, 2015, 59, 1025-1040.	1.5	187
104	Simultaneous bilateral femoral neck fracture and end-stage renal disease in a 76-year-old woman: a case report. Aging Clinical and Experimental Research, 2015, 27, 555-559.	1.4	2
105	Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. Molecular Aspects of Medicine, 2015, 43-44, 66-76.	2.7	63
106	Towards prevention and therapy of Alzheimer's disease. Molecular Aspects of Medicine, 2015, 43-44, 1-2.	2.7	4
107	Novel application of brain-targeting polyphenol compounds in sleep deprivation-induced cognitive dysfunction. Neurochemistry International, 2015, 89, 191-197.	1.9	47
108	Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1202-1208.	1.8	183

#	Article	IF	Citations
109	Childhood and adolescent obesity and longâ€term cognitive consequences during aging. Journal of Comparative Neurology, 2015, 523, 757-768.	0.9	43
110	Chemical investigation of commercial grape seed derived products to assess quality and detect adulteration. Food Chemistry, 2015, 170, 271-280.	4.2	39
111	Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Frontiers in Aging Neuroscience, 2014, 6, 42.	1.7	90
112	The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure. FASEB Journal, 2014, 28, 2120-2133.	0.2	42
113	Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain, 2014, 137, 2271-2286.	3.7	128
114	Epigenetic Mechanisms Linking Diabetes and Synaptic Impairments. Diabetes, 2014, 63, 645-654.	0.3	44
115	Green coffee as a novel agent for Alzheimerâ€™s disease prevention by attenuating diabetes. Translational Neuroscience, 2014, 5, .	0.7	9
116	The Science of Cocoa Flavanols: Bioavailability, Emerging Evidence, and Proposed Mechanisms. Advances in Nutrition, 2014, 5, 547-549.	2.9	13
117	Cocoa Extracts Reduce Oligomerization of Amyloid-Î²: Implications for Cognitive Improvement in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 643-650.	1.2	58
118	P1-079: NOVEL ROLE OF THE DEPRESSION-ASSOCIATED GATA1 TRANSCRIPTION FACTOR IN ALZHEIMER'S DISEASE. , 2014, 10, P332-P332.		3
119	P3-046: INSULIN RESISTANCE AND OBESITY IN CHILDHOOD AND LONG-TERM CONSEQUENCES DURING AGING. , 2014, 10, P645-P645.		0
120	P1-408: TARGETING SYNAPTIC DYSFUNCTION THROUGH DIETARY POLYPHENOL AS A NOVEL THERAPEUTIC INTERVENTION FOR AD. , 2014, 10, P463-P463.		0
121	P3-060: ACTIVATION OF ECTOPICALLY EXPRESSED OLFACTORY RECEPTORS IN THE BRAIN ATTENUATES TAU-PROCESSING IN RESPONSE TO MILD TRAUMATIC BRAIN INJURY. , 2014, 10, P649-P650.		0
122	F1-02-01: EPIGENETIC MECHANISMS LINKING DIABETES AND SYNAPTIC PLASTICITY. , 2014, 10, P125-P125.		0
123	Molecular Topology as Novel Strategy for Discovery of Drugs with AÎ² Lowering and Anti-Aggregation Dual Activities for Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e92750.	1.1	12
124	Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimerâ€™s Disease. Current Alzheimer Research, 2014, 11, 637-644.	0.7	10
125	Select small nucleolar RNAs in blood components as novel biomarkers for improved identification of comorbid traumatic brain injury and post-traumatic stress disorder in veterans of the conflicts in Afghanistan and Iraq. American Journal of Neurodegenerative Disease, 2014, 3, 170-81.	0.1	8
126	Sirtuins as therapeutic targets of ALS. Cell Research, 2013, 23, 1073-1074.	5.7	19

#	Article	IF	Citations
127	Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a mouse model. Molecular Nutrition and Food Research, 2013, 57, 2091-2102.	1.5	38
128	Identification of brainâ€targeted bioactive dietary quercetinâ€3â€•O â€glucuronide as a novel intervention for Alzheimer's disease. FASEB Journal, 2013, 27, 769-781.	0.2	177
129	IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Molecular Immunology, 2013, 56, 619-629.	1.0	33
130	Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-Î³ coactivator 1Î± regulated Î²-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiology of Aging, 2013, 34, 1581-1588.	1.5	287
131	Novel role of red wine-derived polyphenols in the prevention of AlzheimerÊ¼s disease dementia and brain pathology: experimental approaches and clinical implications. Planta Medica, 2013, 79, 92-92.	0.7	0
132	Unintended Effects of Cardiovascular Drugs on the Pathogenesis of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e65232.	1.1	26
133	Investigation of Nebivolol as a Novel Therapeutic Agent for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 1147-1156.	1.2	21
134	Decreased Level of Olfactory Receptors in Blood Cells Following Traumatic Brain Injury and Potential Association with Tauopathy. Journal of Alzheimer's Disease, 2013, 34, 417-429.	1.2	44
135	Identification of brainâ€targeted bioactive dietary quercetinâ€3â€Oâ€glucuronide as a novel intervention for Alzheimer's disease. FASEB Journal, 2013, 27, 1177.5.	0.2	1
136	Repeated dosing and BMI influence plasma polyphenol response in humans. FASEB Journal, 2013, 27, .	0.2	0
137	Chocolate may attenuate cognitive deterioration in Alzheimer's disease through prevention of gene expression related to depressive disorder. FASEB Journal, 2013, 27, 1177.7.	0.2	0
138	Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. FASEB Journal, 2013, 27, 1177.1.	0.2	0
139	Molecular topology as novel strategy for Alzheimer's disease drug discovery. FASEB Journal, 2013, 27, 894.5.	0.2	0
140	Influence of Diabetes on Plasma Pharmacokinetics and Brain Bioavailability of Grape Polyphenols in the Zucker Rat Model. FASEB Journal, 2013, 27, 636.3.	0.2	0
141	Repurposing antiâ€hypertensive drugs for Alzheimer's disease. FASEB Journal, 2013, 27, 1177.6.	0.2	0
142	The science of repurposing drugs in Alzheimer's disease therapeutics: The tale of rexinoid receptor ligand IRX4204. FASEB Journal, 2013, 27, 1177.4.	0.2	0
143	Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice. Nutritional Neuroscience, 2012, 15, 37-45.	1.5	48
144	Novel role of red wine-derived polyphenols in the prevention of AlzheimerÊ¼s disease dementia and brain pathology: experimental approaches and clinical implications. Planta Medica, 2012, 78, E24-E24.	0.7	6

#	Article	IF	Citations
145	Novel Role of Red Wine-Derived Polyphenols in the Prevention of AlzheimerÊ¼s Disease Dementia and Brain Pathology: Experimental Approaches and Clinical Implications. Planta Medica, 2012, 78, 1614-1619.	0.7	58
146	Elevated Plasma MCP-1 Concentration Following Traumatic Brain Injury as a Potential â€œPredispositionâ€• Factor Associated with an Increased Risk for Subsequent Development of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 301-313.	1.2	36
147	Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols. Neurobiology of Aging, 2012, 33, 1427-1439.	1.5	62
148	GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Neurobiology of Aging, 2012, 33, 2072-2081.	1.5	53
149	Brain-Targeted Proanthocyanidin Metabolites for Alzheimer's Disease Treatment. Journal of Neuroscience, 2012, 32, 5144-5150.	1.7	188
150	Enzymatic synthesis of substituted epicatechins for bioactivity studies in neurological disorders. Biochemical and Biophysical Research Communications, 2012, 417, 457-461.	1.0	23
151	Quantification of anthocyanidins in the grapes and grape juice products with acid assisted hydrolysis using LC/MS. Journal of Functional Foods, 2012, 4, 710-717.	1.6	28
152	Insulin Receptor Expression and Activity in the Brains of Nondiabetic Sporadic Alzheimerâ€™s Disease Cases. International Journal of Alzheimer's Disease, 2012, 2012, 1-12.	1.1	14
153	Paired Helical Filaments from Alzheimer Disease Brain Induce Intracellular Accumulation of Tau Protein in Aggresomes. Journal of Biological Chemistry, 2012, 287, 20522-20533.	1.6	117
154	Diffuse disconnectivity in traumatic brain injury: a resting state fMRI and DTI study. Translational Neuroscience, 2012, 3, 9-14.	0.7	42
155	Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease. PLoS ONE, 2012, 7, e49191.	1.1	112
156	Role of Personalized Medicine in the Identification and Characterization of Parkinson?s Disease in Asymptomatic Subjects. , 2012, 02, .		10
157	Traumatic Brain Injury (TBI) Induces Downâ€Regulation of Olfactory Receptors That Are Ectopically Expressed In The Brain: Implications In TBIâ€Mediated Tauopathy. FASEB Journal, 2012, 26, 846.4.	0.2	0
158	Nasal Spray of Bioactive Polyphenol Metabolites as a Novel Therapy for Alzheimer's Disease and Other Forms of Dementia. FASEB Journal, 2012, 26, 846.3.	0.2	0
159	Complementâ€derived anaphylatoxin, C5aâ€mediated signaling pathway is a novel pharmacological target for IVIGâ€regulated humoral immunotherapy in Alzheimer's Disease. FASEB Journal, 2012, 26, 846.5.	0.2	0
160	Bioavailability and Brain Deposition of Proanthocyanidin (PAC), Anthocyanin and Flavonoid in Combiâ€Phenol Treated Rats on High Fat (HF) or Low Fat (LF) Diet. FASEB Journal, 2012, 26, 646.8.	0.2	0
161	Exploring The Molecular Mechanisms Underlying The Efficacy of Mindfulness Based Stress Reduction In Alleviating Psychological Stress in Alzheimer's Disease Caregivers. FASEB Journal, 2012, 26, 846.1.	0.2	0
162	Systems Biology Evaluation of Combiâ€Phenol on Metabolic Syndromeâ€Induced Brain Dysfunction. FASEB Journal, 2012, 26, 626.30.	0.2	0

#	Article	IF	Citations
163	Select non-coding RNA in blood components provide novel clinically accessible biological surrogates for improved identification of traumatic brain injury in OEF/OIF Veterans. American Journal of Neurodegenerative Disease, 2012, 1, 88-98.	0.1	26
164	Survey of Polyphenol Constituents in Grapes and Grape-Derived Products. Journal of Agricultural and Food Chemistry, 2011, 59, 10586-10593.	2.4	73
165	Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of Aging, 2011, 32, 2321.e1-2321.e12.	1.5	54
166	Caloric Intake, Dietary Lifestyles, Macronutrient Composition, and Alzheimerâ€™ Disease Dementia. International Journal of Alzheimer's Disease, 2011, 2011, 1-12.	1.1	9
167	Grape Seed Polyphenolic Extract Specifically Decreases AÎ²*56 in the Brains of Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 26, 657-666.	1.2	49
168	Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. Experimental Neurology, 2011, 232, 1-6.	2.0	81
169	Mitochondrial bioenergetics is defective in presymptomatic Tg2576 AD Mice. Translational Neuroscience, 2011, 2, 1-5.	0.7	20
170	Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1Î±) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Molecular Neurodegeneration, 2011, 6, 51.	4.4	110
171	Preclinical study of dimebon on Î²-amyloid-mediated neuropathology in Alzheimer's disease. Molecular Neurodegeneration, 2011, 6, 7.	4.4	32
172	Potential application of grape derived polyphenols in Huntingtonâ€™s disease. Translational Neuroscience, 2010, 1, 95-100.	0.7	34
173	Deep brain stimulation in midline thalamic region facilitates synaptic transmission and short-term memory in a mouse model of Alzheimerâ€™s disease. Translational Neuroscience, 2010, 1, 188-194.	0.7	27
174	Alzheimerâ€™s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications. Experimental Gerontology, 2010, 45, 15-22.	1.2	34
175	The role of Sirt1: At the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 1690-1694.	1.1	79
176	Development of a grape seed polyphenolic extract with antiâ€oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies. Journal of Neurochemistry, 2010, 114, 1557-1568.	2.1	32
177	SCF^{Fbx2}â€E3â€ligaseâ€mediated degradation of BACE1 attenuates Alzheimerâ€™s disease amyloidosis and improves synaptic function. Aging Cell, 2010, 9, 1018-1031.	3.0	72
178	Role of grape seed polyphenols in Alzheimer’s disease neuropathology. Nutrition and Dietary Supplements, 2010, 2010, 97.	0.7	31
179	Grape-Seed Polyphenolic Extract Improves the Eye Phenotype in aDrosophilaModel of Tauopathy. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	11
180	Carvedilol Reestablishes Long-Term Potentiation in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 649-654.	1.2	31

#	Article	IF	Citations
181	Flavonoids and Isoflavonoids: From Plant Biology to Agriculture and Neuroscience. Plant Physiology, 2010, 154, 453-457.	2.3	271
182	Personalized Medicine in Traumatic Brain Injury. Psychiatric Clinics of North America, 2010, 33, 905-913.	0.7	18
183	Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding. Expert Review of Proteomics, 2010, 7, 579-589.	1.3	30
184	Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 653-661.	1.2	115
185	Carotenoid levels in ageing human brain with reduced cognitive function. FASEB Journal, 2010, 24, 539.5.	0.2	0
186	Role of Grapeâ€Derived Polyphenols in the Prevention of Alzheimer's disease and the Promotion of Healthy Aging. FASEB Journal, 2010, 24, 230.7.	0.2	0
187	nELAV Proteins Alteration in Alzheimer's Disease Brain: A Novel Putative Target for Amyloid-Î² Reverberating on AÎ²PP Processing. Journal of Alzheimer's Disease, 2009, 16, 409-419.	1.2	56
188	PGC-1Î± Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. Archives of Neurology, 2009, 66, 352-61.	4.9	323
189	Dietary composition modulates brain mass and solubilizable AÎ² levels in a mouse model of aggressive Alzheimer's amyloid pathology. Molecular Neurodegeneration, 2009, 4, 40.	4.4	43
190	Grape Seed Polyphenolic Extract as a Potential Novel Therapeutic Agent in Tauopathies. Journal of Alzheimer's Disease, 2009, 16, 433-439.	1.2	75
191	Bioavailability of Gallic Acid and Catechins from Grape Seed Polyphenol Extract is Improved by Repeated Dosing in Rats: Implications for Treatment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 113-124.	1.2	223
192	Identification of Antihypertensive Drugs Which Inhibit Amyloid-Î² Protein Oligomerization. Journal of Alzheimer's Disease, 2009, 16, 49-57.	1.2	67
193	Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration. Journal of Alzheimer's Disease, 2009, 16, 59-72.	1.2	116
194	S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic Î±-Secretase Activity Acts via Selective Promotion of ADAM-10. PLoS ONE, 2009, 4, e4183.	1.1	64
195	Bioavailability of gallic acid and catechins from neuroprotective grape seed extract is improved by repeated dosing in rats. FASEB Journal, 2009, 23, 104.4.	0.2	0
196	Regulation of Forkhead Transcription Factor FoxO3a Contributes to Calorie Restrictionâ€induced Prevention of Alzheimer's Diseaseâ€type Amyloid Neuropathology and Spatial Memory Deterioration. Annals of the New York Academy of Sciences, 2008, 1147, 335-347.	1.8	106
197	Metabolic syndrome and the role of dietary lifestyles in Alzheimerâ€™s disease. Journal of Neurochemistry, 2008, 106, 1503-1514.	2.1	141
198	Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. Journal of Neuroinflammation, 2008, 5, 5.	3.1	52

#	Article	IF	Citations
199	Immunomodulation with Glatiramer Acetate Prevents Long-Term Inflammatory Pain. International Journal of Neuroscience, 2008, 118, 433-453.	0.8	6
200	Effects of Grape Seed-derived Polyphenols on Amyloid Î²-Protein Self-assembly and Cytotoxicity*. Journal of Biological Chemistry, 2008, 283, 32176-32187.	1.6	177
201	Grape-Derived Polyphenolics Prevent AÂ Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2008, 28, 6388-6392.	1.7	339
202	Can diet modifications play a preventative role in the onset of Alzheimerâ€™s disease?. Aging Health, 2008, 4, 1-3.	0.3	1
203	Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. International Journal of Medical Sciences, 2008, 5, 92-99.	1.1	50
204	Systems biology in the study of neurological disorders: focus on Alzheimer's disease. Alcohol Research, 2008, 31, 60-5.	1.0	3
205	Increased Neuronal Injury in Transgenic Mice with Neuronal Overexpression of Human Cyclooxygenase-2 is reversed by Hypothermia and Rofecoxib Treatment. Current Neurovascular Research, 2007, 4, 274-279.	0.4	25
206	Valsartan lowers brain Î²-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 2007, 117, 3393-3402.	3.9	284
207	Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiology of Aging, 2007, 28, 824-830.	1.5	111
208	Moderate consumption of Cabernet Sauvignon attenuates Aï¿½ neuropathology in a mouse model of Alzheimer's disease. FASEB Journal, 2006, 20, 2313-2320.	0.2	283
209	Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer???s Disease?. CNS Drugs, 2006, 20, 85-98.	2.7	22
210	Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophrenia Research, 2006, 84, 1-14.	1.1	142
211	Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction*. Journal of Biological Chemistry, 2006, 281, 21745-21754.	1.6	567
212	Identification of potential CSF biomarkers in ALS. Neurology, 2006, 66, 1218-1222.	1.5	198
213	Microglia Activation in the Brain as Inflammatory Biomarker of Alzheimerâ€™s Disease Neuropathology and Clinical Dementia. Disease Markers, 2006, 22, 95-102.	0.6	100
214	Identification of G-Protein Coupled Receptor Kinase 2 in Paired Helical Filaments and Neurofibrillary Tangles. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1157-1169.	0.9	19
215	Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri) Tj ETQq1 1 0.784314 rgBT /Ove	1.2	172
216	A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neuroscience, 2006, 7, 29.	0.8	241

#	Article	IF	Citations
217	Caloric Intake and Alzheimerâ€™s Disease. , 2006, 35, 159-175.		40
218	The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment. , 2005, , 166-175.		1
219	Caloric restriction attenuates Î²â€amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB Journal, 2005, 19, 1-18.	0.2	240
220	Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistanceâ€associated promotion of Alzheimer's disease Î²â€amyloid neuropathology. FASEB Journal, 2005, 19, 2081-2082.	0.2	38
221	From proteomics to biomarker discovery in Alzheimer's disease. Brain Research Reviews, 2005, 48, 360-369.	9.1	43
222	Expression of tau reduces secretion of AÎ² without altering the amyloid precursor protein content in CHOsw cells. FEBS Letters, 2005, 579, 2119-2124.	1.3	6
223	Expression profile of genes associated with antimetastatic gene:nm23-Mediated metastasis inhibition in breast carcinoma cells. International Journal of Cancer, 2004, 109, 65-70.	2.3	27
224	Dietâ€induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 2004, 18, 902-904.	0.2	583
225	Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1639, 159-168.	1.8	107
226	Transgenic Neuronal Expression of Proopiomelanocortin Attenuates Hyperphagic Response to Fasting and Reverses Metabolic Impairments in Leptin-Deficient Obese Mice. Diabetes, 2003, 52, 2675-2683.	0.3	84
227	A therapeutic role for cyclooxygenaseâ€2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB Journal, 2003, 17, 725-727.	0.2	140
228	Cyclooxygenase (COX)-2 and COX-1 Potentiate Î²-Amyloid Peptide Generation through Mechanisms That Involve Î³-Secretase Activity. Journal of Biological Chemistry, 2003, 278, 50970-50977.	1.6	100
229	Caspase Gene Expression in the Brain as a Function of the Clinical Progression of Alzheimer Disease. Archives of Neurology, 2003, 60, 369.	4.9	108
230	Role of Cyclooxygenase-2 in Neuronal Cell Cycle Activity and Glutamate-Mediated Excitotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 494-500.	1.3	108
231	Cyclooxygenase-2 Promotes Amyloid Plaque Deposition in a Mouse Model of Alzheimer's Disease Neuropathology. Gene Expression, 2002, 10, 271-278.	0.5	110
232	Cyclooxygenase as a Target for the Antiamyloidogenic Activities of Nonsteroidal Anti-Inflammatory Drugs in Alzheimerâ€™s Disease. NeuroSignals, 2002, 11, 293-297.	0.5	13
233	Amyloid Î²-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. Journal of Alzheimer's Disease, 2002, 4, 193-201.	1.2	155
234	Overexpression of Wild Type But Not an FAD Mutant Presenilin-1 Promotes Neurogenesis in the Hippocampus of Adult Mice. Neurobiology of Disease, 2002, 10, 8-19.	2.1	109

#	Article	IF	Citations
235	Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's Disease neuropathology. Neurobiology of Aging, 2002, 23, 327-334.	1.5	107
236	Amyloid immunization in Alzheimerâ€™s disease: do we promote amyloid scavenging at the cost of inflammatory degeneration?. Neurobiology of Aging, 2002, 23, 665-666.	1.5	3
237	AN1792 vaccination immunotherapy in Alzheimerâ€™s disease: the case of a therapy before its time. Neurobiology of Aging, 2002, 23, 683-684.	1.5	12
238	Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed?. Lancet Neurology, The, 2002, 1, 403-404.	4.9	8
239	From cyclooxygenase activities to Alzheimer's disease neuropathology:experimental approaches and therapeutic interventions. Drug Development Research, 2002, 56, 438-445.	1.4	1
240	Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathologica, 2002, 103, 157-162.	3.9	27
241	Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neuroscience Letters, 2001, 298, 191-194.	1.0	101
242	Gene expression profiling of the tau mutant (P301L) transgenic mouse brain. Neuroscience Letters, 2001, 310, 1-4.	1.0	28
243	Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. Archives of Gerontology and Geriatrics, 2001, 33, 13-28.	1.4	62
244	Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspaseâ€ƒ3. Journal of Neurochemistry, 2001, 77, 43-49.	2.1	102
245	Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. Journal of Neuroscience Research, 2001, 65, 471-476.	1.3	120
246	Neuronal Cyclooxygenase 2 Expression in the Hippocampal Formation as a Function of the Clinical Progression of Alzheimer Disease. Archives of Neurology, 2001, 58, 487-92.	4.9	169
247	The potential of selective COX-2 inhibitors in inflammatory and other diseases. Drugs of Today, 2001, 37, 181.	0.7	3
248	Anti-inflammatory and Antioxidant Therapies in Alzheimer's Disease. , 2001, , 487-492.		0
249	The role of cyclooxygenase in Alzheimerâ€™s disease neurodegeneration. , 2001, , 197-207.		0
250	Elevated Plasma Neopterin Levels in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2000, 14, 228-230.	0.6	24
251	The potential of specific COX-2 inhibition. Drug Discovery Today, 2000, 5, 88-89.	3.2	2
252	The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimerâ€™s disease. Journal of Neuroimmunology, 2000, 105, 124-130.	1.1	78

#	Article	IF	Citations
253	Cytokine Gene Expression as a Function of the Clinical Progression of Alzheimer Disease Dementia. Archives of Neurology, 2000, 57, 1153.	4.9	180
254	Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. Journal of Cellular Biochemistry, 1999, 73, 303-311.	1.2	133
255	Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse, 1999, 31, 278-284.	0.6	46
256	Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. Journal of Neuroscience Research, 1999, 57, 295-303.	1.3	219
257	Potentiation of Excitotoxicity in Transgenic Mice Overexpressing Neuronal Cyclooxygenase-2. American Journal of Pathology, 1999, 155, 995-1004.	1.9	218
258	Glycoprotein 330/Megalin (LRP-2) Has Low Prevalence as mRNA and Protein in Brain Microvessels and Choroid Plexus. Experimental Neurology, 1999, 157, 194-201.	2.0	66
259	Protein Kinase C Anchoring Deficit in Postmortem Brains of Alzheimer's Disease Patients. Experimental Neurology, 1999, 159, 559-564.	2.0	79
260	Complementâ€derived anaphylatoxin C5a protects against glutamateâ€mediated neurotoxicity. Journal of Cellular Biochemistry, 1999, 73, 303-311.	1.2	2
261	Cyclooxygenase and inflammation in Alzheimer's disease: Experimental approaches and clinical interventions. Journal of Neuroscience Research, 1998, 54, 1-6.	1.3	171
262	Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. Journal of Neuroimmunology, 1998, 89, 142-149.	1.1	60
263	HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. Journal of the Neurological Sciences, 1998, 161, 66-69.	0.3	19
264	Glucocorticoids in Alzheimer??s Disease. Drugs and Aging, 1998, 12, 1-6.	1.3	38
265	Complement and glutamate neurotoxicity. Molecular and Chemical Neuropathology, 1997, 31, 289-300.	1.0	28
266	Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system. Neurobiology of Aging, 1996, 17, 707-716.	1.5	124
267	Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Molecular Brain Research, 1995, 33, 174-178.	2.5	198
268	Clusterin (apoJ) Alters the Aggregation of Amyloid Î²-Peptide (AÎ²1-42) and Forms Slowly Sedimenting AÎ² Complexes That Cause Oxidative Stress. Experimental Neurology, 1995, 136, 22-31.	2.0	318
269	Expression of complement C1gB and C4 mRNAs during rat brain development. Developmental Brain Research, 1994, 80, 163-174.	2.1	33
270	Clusterin (SGP-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. Journal of Comparative Neurology, 1994, 339, 387-400.	0.9	144

#	Article	IF	Citations
271	TGF-Î²1 is an organizer of responses to neurodgeneration. Journal of Cellular Biochemistry, 1993, 53, 314-322.	1.2	196
272	In Situ Hybridization to Brain Tissue Sections Using Labeled Single-Strand Complementary RNA Probes. , 1992, , 155-166.		1
273	BDNF mRNA expression in the developing rat brain following kainic acid-induced seizure activity. Neuron, 1992, 8, 1127-1138.	3.8	214
274	Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiology of Aging, 1992, 13, 641-648.	1.5	180
275	Ovarian Steroid and Neurotoxin Models of Brain Aging in Rodents. Annals of the New York Academy of Sciences, 1992, 648, 119-124.	1.8	2
276	Sulfated glycoprotein-2 (SGP-2) mRNA is expressed in rat striatal astrocytes following ibotenic acid lesions. Neuroscience Letters, 1991, 130, 1-4.	1.0	55
277	Disappearance of GAD-mRNA and tyrosine hydroxylase in substantia nigra following striatal ibotenic acid lesions: Evidence for transneuronal regression. Experimental Neurology, 1991, 112, 131-139.	2.0	35
278	Tyrosine Hydroxylase mRNA Expression by Dopaminergic Neurons in Culture: Effect of 1 -Methyl-4-Phenylpyridinium Treatment. Journal of Neurochemistry, 1991, 57, 527-532.	2.1	17
279	Tyrosine Hydroxylase mRNA Concentration in Midbrain Dopaminergic Neurons Is Differentially Regulated by Reserpine. Journal of Neurochemistry, 1990, 55, 1793-1799.	2.1	47
280	Castration Enhances Expression of Glial Fibrillary Acidic Protein and Sulfated Glycoprotein-2 in the Intact and Lesion-Altered Hippocampus of the Adult Male Rat. Molecular Endocrinology, 1990, 4, 1995-2002.	3.7	113
281	Combined in situ hybridization and immunocytochemistry in the assay of pharmacological effects on tyrosine hydroxylase mRNA concentration. Pharmacological Research, 1989, 21, 299-311.	3.1	32
282	Selective reduction of mRNA for the Î²-amyloid precursor protein that lacks a Kunitz-type protease inhibitor motif in cortex from Alzheimer brainsâ˜†. Experimental Neurology, 1988, 102, 264-268.	2.0	95
283	Cyclooxygenase (COX)-2 and Clinical Progression of Alzheimer's Disease Dementia: Implications in the Role of Neuronal COX-2 in Cell Cycle. , 0, , 379-392.		1
284	Peroxisome Proliferator Activator Receptor Gamma Coactivator-1Î± Overexpression in Amyotrophic Lateral Sclerosis: A Tale of Two Transgenics. SSRN Electronic Journal, 0, , .	0.4	0